F. Liew, N. Pitman, and I. Mcinnes, Disease-associated functions of IL-33: the new kid in the IL-1 family, Nature Reviews Immunology, vol.173, issue.2, pp.103-113, 2010.
DOI : 10.1038/nri2692

T. Theoharides, A. Petra, A. Taracanova, S. Panagiotidou, and P. Conti, Targeting IL-33 in Autoimmunity and Inflammation, Journal of Pharmacology and Experimental Therapeutics, vol.354, issue.1, pp.24-31, 2015.
DOI : 10.1124/jpet.114.222505

N. Millar, G. Murrell, and I. Mcinnes, Alarmins in tendinopathy: unravelling new mechanisms in a common disease, Rheumatology, vol.52, issue.5, pp.769-79, 2013.
DOI : 10.1093/rheumatology/kes409

J. Schmitz, A. Owyang, E. Oldham, Y. Song, E. Murphy et al., IL-33, an Interleukin-1-like Cytokine that Signals via the IL-1 Receptor-Related Protein ST2 and Induces T Helper Type 2-Associated Cytokines, Immunity, vol.23, issue.5, pp.479-90, 2005.
DOI : 10.1016/j.immuni.2005.09.015

B. Stolarski, M. Kurowska-stolarska, P. Kewin, D. Xu, and F. Liew, IL-33 Exacerbates Eosinophil-Mediated Airway Inflammation, The Journal of Immunology, vol.185, issue.6, pp.3472-80, 1950.
DOI : 10.4049/jimmunol.1000730

D. Xu, H. Jiang, P. Kewin, Y. Li, R. Mu et al., IL-33 exacerbates antigen-induced arthritis by activating mast cells, Proceedings of the National Academy of Sciences, vol.105, issue.31, pp.10913-10921, 2008.
DOI : 10.1073/pnas.0801898105
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2491487

D. Xu, H. Jiang, Y. Li, P. Pushparaj, M. Kurowska-stolarska et al., IL-33 Exacerbates Autoantibody-Induced Arthritis, The Journal of Immunology, vol.184, issue.5, pp.2620-2626, 2010.
DOI : 10.4049/jimmunol.0902685

S. Athari, E. Poirier, J. Biton, L. Semerano, R. Hervé et al., Collagen-induced arthritis and imiquimod-induced psoriasis develop independently of interleukin-33, Arthritis Research & Therapy, vol.53, issue.Suppl 2, p.143, 2016.
DOI : 10.1186/s13075-016-1042-x

E. Kunisch, S. Chakilam, M. Gandesiri, and R. Kinne, IL-33 regulates TNF-?? dependent effects in synovial fibroblasts, International Journal of Molecular Medicine, vol.29, issue.4, pp.530-570, 2012.
DOI : 10.3892/ijmm.2012.883
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573710

J. Malcolm, R. Awang, J. Oliver-bell, J. Butcher, L. Campbell et al., IL-33 Exacerbates Periodontal Disease through Induction of RANKL, Journal of Dental Research, vol.184, issue.5, pp.968-75, 2015.
DOI : 10.1016/j.immuni.2005.09.015

E. Lee, M. So, S. Hong, Y. Kim, B. Yoo et al., Interleukin-33 acts as a transcriptional repressor and extracellular cytokine in fibroblast-like synoviocytes in patients with rheumatoid arthritis, Cytokine, vol.77, pp.35-43, 2016.
DOI : 10.1016/j.cyto.2015.10.005

Z. Xiangyang, Y. Lutian, Z. Lin, X. Liping, S. Hui et al., Increased levels of interleukin-33 associated with bone erosion and interstitial lung diseases in patients with rheumatoid arthritis, Cytokine, vol.58, issue.1, pp.6-9, 2012.
DOI : 10.1016/j.cyto.2011.12.010

J. Shen, Q. Shang, C. Wong, E. Li, S. Wang et al., IL-33 and soluble ST2 levels as novel predictors for remission and progression of carotid plaque in early rheumatoid arthritis: A prospective study, Seminars in Arthritis and Rheumatism, vol.45, issue.1, pp.18-27, 2015.
DOI : 10.1016/j.semarthrit.2015.02.001

P. Martin, D. Talabot-ayer, C. Seemayer, S. Vigne, C. Lamacchia et al., Disease severity in K/BxN serum transfer-induced arthritis is not affected by IL-33 deficiency, Arthritis Research & Therapy, vol.15, issue.1, p.13, 2013.
DOI : 10.1016/j.it.2009.06.001

D. Talabot-ayer, P. Martin, C. Seemayer, S. Vigne, C. Lamacchia et al., Immune-mediated experimental arthritis in IL-33 deficient mice, Cytokine, vol.69, issue.1, pp.68-74, 2014.
DOI : 10.1016/j.cyto.2014.05.007

F. Rivellese, J. Suurmond, K. Habets, A. Dorjée, N. Ramamoorthi et al., Ability of Interleukin-33- and Immune Complex-Triggered Activation of Human Mast Cells to Down-Regulate Monocyte-Mediated Immune Responses, Arthritis & Rheumatology, vol.15, issue.Suppl 2, pp.2343-53, 2015.
DOI : 10.1002/art.39192

M. Komai-koma, D. Gilchrist, A. Mckenzie, C. Goodyear, D. Xu et al., IL-33 Activates B1 Cells and Exacerbates Contact Sensitivity, The Journal of Immunology, vol.186, issue.4, pp.2584-91, 1950.
DOI : 10.4049/jimmunol.1002103

A. Ahmed and M. Koma, Interleukin-33 Triggers B1 Cell Expansion and Its Release of Monocyte/Macrophage Chemoattractants and Growth Factors, Scandinavian Journal of Immunology, vol.14, issue.10, pp.118-142, 2015.
DOI : 10.1111/sji.12312

S. Sattler, G. Ling, D. Xu, L. Hussaarts, R. A. Zhao et al., IL-10-producing regulatory B cells induced by IL-33 (BregIL-33) effectively attenuate mucosal inflammatory responses in the gut, Journal of Autoimmunity, vol.50, pp.107-129, 2014.
DOI : 10.1016/j.jaut.2014.01.032

J. Sellam, S. Marion-thore, F. Dumont, S. Jacques, H. Garchon et al., Use of Whole-Blood Transcriptomic Profiling to Highlight Several Pathophysiologic Pathways Associated With Response to Rituximab in Patients With Rheumatoid Arthritis: Data From a Randomized, Controlled, Open-Label Trial, Arthritis & Rheumatology, vol.12, issue.Suppl 2, pp.2015-2040, 2014.
DOI : 10.1002/art.38671

X. Mariette, S. Rouanet, J. Sibilia, B. Combe, L. Loët et al., Evaluation of low-dose rituximab for the retreatment of patients with active rheumatoid arthritis: a non-inferiority randomised controlled trial, Annals of the Rheumatic Diseases, vol.64, issue.Supp 10, pp.1508-1522, 2014.
DOI : 10.1136/annrheumdis-2013-203480

A. Van-gestel, J. Anderson, P. Van-riel, M. Boers, C. Haagsma et al., ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials American College of Rheumatology European League of Associations for Rheumatology, J Rheumatol, vol.26, issue.3, pp.705-716, 1999.

J. Sellam, H. Hendel-chavez, S. Rouanet, N. Vernet, B. Ly et al., Serum IL-33 level is increased in rheumatoid arthritis and predicts response to rituximab in combination with high serum IgG level and autoantibody positivity: an open-label, prospective, multicentre biological trial, Arthritis Rheum, vol.66, pp.1279-80, 2014.

E. Rivière, B. Ly, S. Boudaoud, H. Chavez, G. Nocturne et al., Pitfalls for detecting interleukin-33 by ELISA in the serum of patients with primary Sj??gren syndrome: comparison of different kits, Annals of the Rheumatic Diseases, vol.73, issue.3, pp.633-638, 2016.
DOI : 10.1136/annrheumdis-2015-208557

J. Sellam, H. Hendel-chavez, S. Rouanet, K. Abbed, B. Combe et al., B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: A six-month, national, multicenter, open-label study, Arthritis & Rheumatism, vol.62, issue.Suppl, pp.933-941, 2011.
DOI : 10.1002/art.30233

M. Couderc, S. Mathieu, B. Pereira, B. Glace, and M. Soubrier, Predictive Factors of Rituximab Response in Rheumatoid Arthritis: Results From a French University Hospital, Arthritis Care & Research, vol.11, issue.4, pp.648-52, 2013.
DOI : 10.1002/acr.21865

M. Van-den-broek, K. Visser, C. Allaart, and T. Huizinga, Personalized medicine: predicting responses to therapy in patients with RA, Current Opinion in Pharmacology, vol.13, issue.3, pp.463-472, 2013.
DOI : 10.1016/j.coph.2013.03.006